OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia's plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a.

businesswire.com - 2026-07-12 19:00:00

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

prnewswire.com - 2026-07-01 22:16:00

Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.

wsj.com - 2026-07-01 19:59:00

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Direct.

businesswire.com - 2026-06-24 03:05:00

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previ.

businesswire.com - 2026-06-15 12:00:00

Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved ​drug Sotyktu in a late-stage head-to-head study.

reuters.com - 2026-06-11 07:03:31

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority.

businesswire.com - 2026-06-11 07:00:00

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease in pediatric patients ages 2 years and older. If approved, ENTYVIO would be the only gut-focused treatment option for these patients. This milest.

businesswire.com - 2026-06-09 16:30:00

On June 01, 2026, Takeda Pharmaceutical Co Ltd (TAK) shares fell 4.8% to $15.19. The stock has faced a decline over the past month, with a 1-week drop of 6.5% a

gurufocus.com - 2026-06-01 18:23:00

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

zacks.com - 2026-05-22 13:15:26

BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.

businesswire.com - 2026-05-18 17:51:00

A ​U.S. jury on ‌Monday found that ​Takeda ​Pharmaceutical caused pharmacies, ⁠insurers, ​retailers and ​others to sustain about $885 million ​in ​damages delaying the ‌release ⁠of a generic version of ​its ​anti-constipation ⁠drug Amitiza ​through an ​anticompetitive ⁠scheme.

reuters.com - 2026-05-18 14:53:52

TAK's FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse's generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new transformation program with cost-cutting measures that will target over $1.3 billion in annualized gross savings by FY2028. As such, I believe TAK's long-term bull case depends on three near-term launch candidates (i.e., the first wave) with oveporexton, rusfertide, and zasocitinib.

seekingalpha.com - 2026-05-18 06:29:41

Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program.

marketbeat.com - 2026-05-15 08:13:37

Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with ​a restructuring to centralize corporate functions and reduce ‌costs.

reuters.com - 2026-05-13 16:49:51

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was parti.

businesswire.com - 2026-05-13 02:38:00

Takeda Pharmaceutical ​said its ‌experimental drug ​for ​primary immunodeficiency disease, ⁠a ​rare condition ​that weakens the ​immune ​system, has met ‌the ⁠main goal of a ​mid- ​to ⁠late-stage ​clinical trial.

reuters.com - 2026-05-04 08:12:22

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.

businesswire.com - 2026-05-04 08:00:00

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com - 2026-04-30 10:40:34

ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.

zacks.com - 2026-04-24 15:26:27

Assetmark Inc. grew its stake in Takeda Pharmaceutical Co. (NYSE: TAK) by 27.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,120 shares of the company's stock after purchasing an additional 33,902 shares during the period. Assetmark Inc.'s holdings in

defenseworld.net - 2026-04-21 03:24:58